What is the difference between Cyclophosphamide Injection and Gemcitabine Hydrochloride?

Cyclophosphamide Injection and Gemcitabine Hydrochloride are both Chemotherapys, so they work through the same broad mechanism. They differ in dosing, half-life, side-effect frequency, and how individual patients tolerate them. See the head-to-head sections below for the specifics.

Can Cyclophosphamide Injection and Gemcitabine Hydrochloride be used for the same conditions?

Both medications are prescribed for overlapping indications including Hodgkin's disease and lymphocytic lymphoma (nodular or diffuse). Always verify with your prescriber and the current FDA label before switching.

Is Cyclophosphamide the same as Gemcitabine?

No. Cyclophosphamide (Cyclophosphamide Injection) and Gemcitabine (Gemcitabine Hydrochloride) are distinct medications. They are sometimes confused because of similar branding or because they treat overlapping conditions, but they have different active ingredients and different safety profiles.

Which has fewer side effects, Cyclophosphamide Injection or Gemcitabine Hydrochloride?

Side-effect frequency varies by individual. The side-effect comparison section on this page shows FAERS-reported events for each drug side by side. FAERS is voluntary reporting, so it reflects what patients and clinicians chose to report, not absolute population risk.

Can I switch from Cyclophosphamide Injection to Gemcitabine Hydrochloride?

Switching medications should always be done under prescriber supervision. The "patient stories" section on this page includes accounts from people who have made the switch and what their transition felt like, but those are individual experiences, not protocols.

Cyclophosphamide Injection vs Gemcitabine Hydrochloride

Compare Cyclophosphamide Injection (Cyclophosphamide) and Gemcitabine Hydrochloride (Gemcitabine), clinical data, side effects, and patient experiences.

Cyclophosphamide Injection

Cyclophosphamide · Chemotherapy

How it works

12.1 Mechanism of Action The mechanism of action has not been fully characterized. However, cross-linking of tumor cell DNA may be involved. The active alkylating metabolites of cy...

Approved for

Hodgkin's disease

lymphocytic lymphoma (nodular or diffuse)

mixed-cell type lymphoma

histiocytic lymphoma

IntravenousTablet

Gemcitabine Hydrochloride

Gemcitabine · Chemotherapy

How it works

12.1 Mechanism of Action Gemcitabine kills cells undergoing DNA synthesis and blocks the progression of cells through the G1/S-phase boundary. Gemcitabine is metabolized by nucleos...

Approved for

1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin

for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) • in combination with paclitaxel

for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy

IntravenousTablet

Quick Comparison

Cyclophosphamide InjectionGemcitabine Hydrochloride

Drug Class

Chemotherapy

Route

Intravenous

Half-Life

N/A

FDA Approved

N/A

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

Cyclophosphamide Injection

Drug Not Working

1-10%

Fever

1-10%

Nausea

1-10%

Diarrhea

0.1-1%

Vomiting

0.1-1%

Gemcitabine Hydrochloride

Drug Not Working

1-10%

Fever

1-10%

Nausea

1-10%

Diarrhea

1-10%

Vomiting

1-10%

Fatigue

1-10%

Shortness of Breath

0.1-1%

FDA Warnings

Cyclophosphamide Injection

5 WARNINGS AND PRECAUTIONS • Myelosuppression, Immunosuppression, Bone Marrow Failure and Infections - Severe immunosuppression may lead to serious and sometimes fatal infections
2 ) • Cardiotoxicity - Myocarditis, myopericarditis, pericardial effusion, arrhythmias and congestive heart failure, which may be fatal, have been reported
Monitor patients, especially those with risk factors for cardio toxicity or pre-existing cardiac disease
5 ) • Veno-occlusive Liver Disease - Fatal outcome can occur

Gemcitabine Hydrochloride

5 WARNINGS AND PRECAUTIONS • Schedule-Dependent Toxicity: Increased toxicity with infusion time greater than 60 minutes or dosing more frequently than once weekly
2 Myelosuppression Myelosuppression manifested by neutropenia, thrombocytopenia, and anemia, occurs with gemcitabine as a single agent and the risks are increased when gemcitabine is combined with other cytotoxic drugs
3 Severe Cutaneous Adverse Reactions (SCARs) SCARs, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP), which can be life-threatening or fatal, have been reported in association with gemcitabine treatment [see Adverse Reactions (6
In some cases, these pulmonary events can lead to fatal respiratory failure despite the discontinuation of therapy

Clinical Trial Data

No head-to-head clinical studies found for Cyclophosphamide Injection vs Gemcitabine Hydrochloride.

Cyclophosphamide Injection vs Gemcitabine Hydrochloride: What You Should Know

Key Differences

Both Cyclophosphamide Injection and Gemcitabine Hydrochloride belong to the Chemotherapy class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.

Safety Considerations

Cyclophosphamide Injection carries 4 FDA warnings. Gemcitabine Hydrochloride carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

Cisplatin vs Cyclophosphamide Injection→Capecitabine vs Cyclophosphamide Injection→Cyclophosphamide Injection vs Paclitaxel→Cyclophosphamide Injection vs Etoposide→Cyclophosphamide For Injection vs Cyclophosphamide Injection→Cyclophosphamide Injection vs Gemcitabine→

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

Cyclophosphamide Injection: DailyMed label · FAERS adverse events · ClinicalTrials.gov
Gemcitabine Hydrochloride: DailyMed label · FAERS adverse events · ClinicalTrials.gov

Loading comparison data...

Cyclophosphamide Injection vs Gemcitabine Hydrochloride

Compare Cyclophosphamide Injection (Cyclophosphamide) and Gemcitabine Hydrochloride (Gemcitabine), clinical data, side effects, and patient experiences.

Cyclophosphamide Injection

Cyclophosphamide · Chemotherapy

How it works

12.1 Mechanism of Action The mechanism of action has not been fully characterized. However, cross-linking of tumor cell DNA may be involved. The active alkylating metabolites of cy...

Approved for

Hodgkin's disease

lymphocytic lymphoma (nodular or diffuse)

mixed-cell type lymphoma

histiocytic lymphoma

IntravenousTablet

Gemcitabine Hydrochloride

Gemcitabine · Chemotherapy

How it works

12.1 Mechanism of Action Gemcitabine kills cells undergoing DNA synthesis and blocks the progression of cells through the G1/S-phase boundary. Gemcitabine is metabolized by nucleos...

Approved for

1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin

for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) • in combination with paclitaxel

for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy

IntravenousTablet

Quick Comparison

Cyclophosphamide InjectionGemcitabine Hydrochloride

Drug Class

Chemotherapy

Route

Intravenous

Half-Life

N/A

FDA Approved

N/A

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

Cyclophosphamide Injection

Drug Not Working

1-10%

Fever

1-10%

Nausea

1-10%

Diarrhea

0.1-1%

Vomiting

0.1-1%

Gemcitabine Hydrochloride

Drug Not Working

1-10%

Fever

1-10%

Nausea

1-10%

Diarrhea

1-10%

Vomiting

1-10%

Fatigue

1-10%

Shortness of Breath

0.1-1%

FDA Warnings

Cyclophosphamide Injection

5 WARNINGS AND PRECAUTIONS • Myelosuppression, Immunosuppression, Bone Marrow Failure and Infections - Severe immunosuppression may lead to serious and sometimes fatal infections
2 ) • Cardiotoxicity - Myocarditis, myopericarditis, pericardial effusion, arrhythmias and congestive heart failure, which may be fatal, have been reported
Monitor patients, especially those with risk factors for cardio toxicity or pre-existing cardiac disease
5 ) • Veno-occlusive Liver Disease - Fatal outcome can occur

Gemcitabine Hydrochloride

5 WARNINGS AND PRECAUTIONS • Schedule-Dependent Toxicity: Increased toxicity with infusion time greater than 60 minutes or dosing more frequently than once weekly
2 Myelosuppression Myelosuppression manifested by neutropenia, thrombocytopenia, and anemia, occurs with gemcitabine as a single agent and the risks are increased when gemcitabine is combined with other cytotoxic drugs
3 Severe Cutaneous Adverse Reactions (SCARs) SCARs, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP), which can be life-threatening or fatal, have been reported in association with gemcitabine treatment [see Adverse Reactions (6
In some cases, these pulmonary events can lead to fatal respiratory failure despite the discontinuation of therapy

Clinical Trial Data

No head-to-head clinical studies found for Cyclophosphamide Injection vs Gemcitabine Hydrochloride.

Cyclophosphamide Injection vs Gemcitabine Hydrochloride: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

Cyclophosphamide Injection: DailyMed label · FAERS adverse events · ClinicalTrials.gov
Gemcitabine Hydrochloride: DailyMed label · FAERS adverse events · ClinicalTrials.gov